Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
Presented for research literature review only van Lieshout EM et al
Retatrutide's triple-agonist mechanism (GLP-1 + GIP + glucagon) produces diarrhea in approximately 34% of users at 12 mg, compared to roughly 30% for semaglutide at 2.4 mg
A systematic search of PubMed and Scopus databases was conducted for articles published between January 2018 and March 2025
Our medical suggestion is to have one Vitamin B12 injection at weekly intervals, up to five shots (so five shots over five weeks)
Retatrutide's subcutaneous bioavailability is approximately 95% based on Phase 1 pharmacokinetic data (Coskun et al., 2022), which is high relative to other compounds in this drug class
US$ 28.00
US$ 28.02
US$ 25.83
US$ 27.36
